EurekAlert!

Triple therapy halves exacerbations in moderate-to-severe COPD

Patients with moderate to severe chronic obstructive pulmonary disease (COPD) can benefit from triple therapy that includes a long-acting β-agonist (LABA), an inhaled corticosteroid (ICS) and an ...
Healio

Benralizumab reduces severe asthma exacerbations, regardless of early improvement in FEV1

Please provide your email address to receive an email when new articles are posted on . Patients with oral corticosteroid-dependent, severe eosinophilic asthma treated with benralizumab achieved ...
European Medical Journal

Does Bisoprolol Benefit Patients with COPD?

A major trial finds the beta blocker bisoprolol neither improves nor worsens outcomes in people with COPD, despite the ...
PharmiWeb

NICE issued final draft guidance recommending dupilumab for eligible COPD patients, positioning it to become the first NHS-recommended biologic for COPD tr…

The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...
MedPage Today

First-Ever Biologic Approved for COPD

The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease (COPD), Sanofi and Regeneron announced on Friday. An injectable interleukin ...
The American Journal of Managed Care

Lymphocyte-HDL Ratio Outperforms Other Biomarkers for Predicting Pulmonary Function in COPD

Investigators found that the ratio of lymphocytes to high-density lipoprotein (HDL) performed better in predicting pulmonary function than the neutrophil-lymphocyte ratio and the platelet-lymphocyte ...